跳至主要内容
临床试验/NCT04691427
NCT04691427招募中早期 1 期

Effectiveness of Vision Therapy in a Virtual Reality Headset

OculoMotor Technologies4 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2021年10月14日最近更新:
适应症

试验速览

阶段
早期 1 期
状态
招募中
入组人数
50
试验地点
4
主要终点
Positive Fusional Vergence

研究概览

简要总结

The purpose of this research study is to see how well the treatment of a participant's eye coordination and/or focusing problems improves eye muscle responses and symptoms of eyestrain. We will use an entertainment device called a virtual reality headset to play a custom-designed video game to find out how well the treatment of binocular vision improves a participant's coordination and/or focusing problem. The virtual reality headset uses eye-trackers to monitor progress in a totally objective manner. Objective testing allows the doctor to determine the results without relying on a participant's ability to answer questions or respond verbally in any way. We will compare the results of a participant before and after playing the video game.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

盲法说明

Examiner (Outcomes Assessor) will be masked by pooling participants from another study.

入排标准

年龄范围
9 Years 至 35 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Age 9 years and older
  • CISS score ≥ 16
  • Best-corrected distance visual acuity of 20/25 or better in each eye
  • Random dot stereopsis appreciation of 500 seconds of arc or better
  • Parent or subject understands the protocol and is willing to enroll in the study

排除标准

  • Constant strabismus at distance or near
  • Vertical heterophoria ≥ 2 ∆ at distance or near
  • ≥ 2 line interocular difference in best-corrected visual acuity
  • Near point of accommodation > 20 cm in either eye as measured by push-up method
  • Manifest or latent nystagmus
  • Non-strabismic binocular vision and accommodative disorders associated with known disease of the brain
  • Diseases known to affect accommodation, vergence, or ocular motility such as multiple sclerosis, Graves orbitopathy, myasthenia gravis, diabetes mellitus, Parkinson disease
  • Any ocular or systemic medication known to affect accommodation or vergence such as anti-anxiety agents (e.g., Librium or Valium), anti-arrhythmic agents (e.g., Cifenline, Cibenzoline), anti-cholinergics, bladder spasmolytic drugs (e.g., Propiverine), hydroxychloroquine, chloroquine, phenothiazines (e.g., Compazine, Mellaril, Thorazine), tricyclic antidepressants (e.g., Elavil, Nortriptyline, Tofranil)
  • Inability to comprehend and/or perform any study-related test or procedure

结局指标

主要结局

Positive Fusional Vergence

时间窗: up to 4 weeks post-therapy

Normal range is \>15 Prism Diopters

Near Point of Convergence

时间窗: up to 4 weeks post-therapy

Normal range is \< 6 cm

次要结局

  • Convergence Insufficiency Symptom Survey (CISS)(up to 4 weeks post-therapy)
  • Vision Quality of Life with Time Survey (VisQuaL-T)(up to 4 weeks post-therapy)
  • Core Elements of Gaming Experience Questionnaire(up to 4 weeks post-therapy)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验